Abstract
Lamivudine is the negative enantiomer of 2'-deoxy-3'- thiacytidine, the racemic mixture of the two enantiomers previously known as both BCH 189 and GR103365X. It is a member of the nucleoside analog reverse transcriptase inhibitor class of antiretroviral drugs. This dideoxynucleoside analog of cytidine is a potent inhibitor of HIV-1 and HIV-2, as well as of hepatitis B virus. Lamivudine- manufactured by GlaxoSmithKline, approved by the US Food and Drug Administration (FDA) approved in 1995, and marketed by ViiV Healthcare-is registered for the treatment of HIV-1 infection and hepatitis B virus infection in a number of countries. Its trade name is Epivir, but it also comes in a number of fixed formulations, including with zidovudine (Combivir), with zidovudine and abacavir (Trizivir), and with abacavir as a single tablet (Kivexa, Epzicom). A tenofovir-lamivudine combination tablet, manufactured by Hetero Drugs in India, was approved by the FDA for use outside the USA (US Food and Drug Administration, 2009).
| Original language | English |
|---|---|
| Title of host publication | Kucers the Use of Antibiotics |
| Subtitle of host publication | A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs |
| Editors | M. Lindsay Grayson |
| Place of Publication | Boca Raton FL USA |
| Publisher | CRC Press |
| Pages | 3729-3754 |
| Number of pages | 26 |
| Edition | 7th |
| ISBN (Electronic) | 9781498747967 |
| ISBN (Print) | 9781498747950 |
| Publication status | Published - 2 Oct 2017 |
